Onset of Action and Sedation Management with Rexulti (Brexpiprazole)
Rexulti requires 10-12 days to reach steady-state concentrations, with clinical separation from placebo typically occurring between 6-12 weeks, making it unsuitable for acute agitation management. 1, 2, 3
Onset of Action Timeline
Brexpiprazole has a 91-hour terminal elimination half-life, with peak plasma concentrations occurring within 4 hours of administration but steady-state not achieved until 10-12 days of daily dosing 1. More importantly for clinical practice, the three phase 3 trials in Alzheimer's-related agitation showed that brexpiprazole took 6-12 weeks to separate from placebo 2, 3. This delayed onset means:
- Do not use Rexulti as a PRN or "as needed" medication for breakthrough agitation 4
- This is a maintenance medication only, not for acute symptom control 4
- Patients and caregivers need clear expectations about the prolonged time to therapeutic effect
Managing Sedation During Titration
Recommended Titration Schedule
Start at 0.5-1 mg daily and increase to 2 mg on days 5-7, with further titration to target dose (2-3 mg) by day 8-14 1, 5. The FDA label specifies:
- Day 1-4: 0.5-1 mg once daily
- Day 5-7: 2 mg once daily
- Day 8+: Target dose of 2-3 mg once daily (maximum 3 mg for agitation in Alzheimer's disease)
Sedation Management Strategies
If sedation occurs, administer the dose at bedtime rather than reducing the dose initially, as sedation often improves with continued use 1. Key considerations:
- Common sedation-related adverse events: Somnolence (6.1% vs 3.6% placebo) and dizziness (5.7% vs 3.0% placebo) 2
- Brexpiprazole has weak histamine H1 receptor affinity (19 nM), suggesting lower sedation risk compared to other antipsychotics 1, 6
- Unlike high-potency typical antipsychotics, brexpiprazole shows relatively low incidence of akathisia (5.5% vs 4.6% placebo) 5
Bridging the Gap: Managing Acute Agitation While Waiting for Onset
Because brexpiprazole takes 6-12 weeks to become effective, you must use alternative strategies for acute agitation during the titration period 3:
For acute breakthrough agitation during titration:
- First-line: Environmental modifications, reorientation, addressing reversible causes (pain, constipation, urinary retention) 7
- PRN medications if needed:
- Lorazepam 0.25-0.5 mg SC/IV q1h PRN (use lower doses in elderly or when co-administered with antipsychotics) 7
- Haloperidol 0.25-0.5 mg PO/SC q1h PRN (start low in elderly, titrate gradually) 7
- Caution: Combining benzodiazepines with high-dose olanzapine has been associated with fatalities; use lower benzodiazepine doses when combining with any antipsychotic 7
Dose Adjustments for Special Populations
Reduce brexpiprazole dose by 50% in patients taking strong CYP2D6 or CYP3A4 inhibitors, and by 75% if taking both 1:
- Strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): Reduce to 50% of usual dose
- Strong CYP3A4 inhibitors (itraconazole, clarithromycin): Reduce to 50% of usual dose
- Both inhibitors present: Reduce to 25% of usual dose
- Poor CYP2D6 metabolizers: Reduce dose by 50%
In moderate renal impairment, exposure is higher; consider starting at the lower end of the dosing range 1.
Critical Safety Considerations
Brexpiprazole carries a black box warning for increased mortality in elderly patients with dementia-related psychosis, similar to all antipsychotics used for this indication 4. Document informed consent discussions about this risk.
Monitor for orthostatic hypotension, particularly during titration, as brexpiprazole has antagonist activity at noradrenergic α1A, α1B, α1D, and α2C receptors 1. Check orthostatic vital signs if dizziness occurs.
Weight gain is the most common adverse event (≥4% and twice placebo rate), with approximately 10% of patients gaining ≥7% body weight in short-term trials 5. Monitor weight and metabolic parameters, though effects on glucose and lipids appear small 5.